From the 73 FFPE tumor samples, we randomly selected 45 samples with wild-type BRAF and all 15 samples with BRAF V600 mutations as per Idylla and subjected these 60 samples to the cobas BRAF V600 Mutation Test, a U.S. Food and Drug Administration–approved companion diagnostic, according to manufacturer's instructions. Here, BRAF is linked to neoplasm.